Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 4/20 | 0.48 |
| ▸ | DDO | Q99489 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | MPL | P40238 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4743563 | 0.85 | DAO (0.59) | DAODDOLMNATSHRKDM4E | |
| SCHEMBL1882229 | 0.84 | GLA (0.52) | LMNATSHRKDM4EGAAGLA | |
| SCHEMBL1369128 | 0.83 | DAO (0.50) | DAODDOKDM4EGAAALDH1A1 | |
| SCHEMBL31423096 | 0.80 | LCK (0.48) | DAODDOTSHRKDM4EGAA | |
| SCHEMBL10509208 | 0.80 | XDH (0.50) | DAODDOLMNATSHRKDM4E | |
| Zinc Ion SCHEMBL1452758 | 0.79 | DAO (0.46) | DAODDOKDM4EALDH1A1HPGD | |
| SCHEMBL1452771 | 0.79 | DAO (0.46) | DAODDOKDM4EALDH1A1HPGD | |
| SCHEMBL3632228 | 0.77 | PADI4 (0.56) | DAODDOLMNATSHRKDM4E | |
| SCHEMBL18553954 | 0.76 | ALDH1A1 (0.47) | LMNATSHRKDM4ECNR2ALDH1A1 | |
| SCHEMBL866250 | 0.74 | DAO (0.65) | DAODDOKDM4EGLAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858825-A1 | BICYCLIC-FUSED HETEROARYL COMPOUNDS AS IRAK4 MODULATORS | Pfizer Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858825-A1 | BICYCLIC-FUSED HETEROARYL COMPOUNDS AS IRAK4 MODULATORS | Pfizer Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3341367-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | PFIZER (US) | 2021-02-24 | — | — | EP | disclosed |
| EP-3341367-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | PFIZER (US) | 2021-02-24 | — | — | EP | disclosed |
| CN-107949559-B | Bicyclic fused heteroaryl or aryl compounds as IRAK4 modulators | 辉瑞公司 | 2020-12-11 | — | — | CN | disclosed |
| US-10316018-B2 | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316018-B2 | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190092750-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | PFIZER INC. (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190092750-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | PFIZER INC. (US) | 2019-03-28 | — | — | US | disclosed |
| US-10174000-B2 | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | PFIZER INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174000-B2 | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | PFIZER INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180244646-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | PFIZER INC. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3341367-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | Pfizer Inc (US) | 2018-07-04 | — | — | EP | disclosed |
| CN-107949559-A | Bicyclic fused heteroaryl or aryl compounds as IRAK4 modulators | 辉瑞公司 | 2018-04-20 | — | — | CN | disclosed |
| WO-2017033093-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | PFIZER INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017033093-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | PFIZER INC. (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316018-B2 | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | IRAK4, IRAK2, IRAK3 | DAO 3728/4885DDO 3175/4885LMNA 1827/4885 |
| US-10174000-B2 | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | IRAK4, IRAK2, IRAK3 | DAO 3728/4885DDO 3175/4885LMNA 1827/4885 |
| US-20180244646-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | IRAK4, IRAK2, IRAK3 | DAO 3728/4885DDO 3175/4885LMNA 1827/4885 |
| US-20190092750-A1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AS IRAK4 MODULATORS | IRAK4, IRAK2, IRAK3 | DAO 3933/4885DDO 3367/4885LMNA 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.